{"id":2685,"company":{"country":"US","currency":"USD","exchange":"NASDAQ NMS - GLOBAL MARKET","ipo":"2019-07-03","marketCap":191.05560302734375,"name":"Clearpoint Neuro Inc","phone":"19499006833","outstanding":24.6200008392334,"symbol":"CLPT","website":"https://www.clearpointneuro.com/","industry":"Health Care"},"price":7.65,"year":2024,"month":1,"day":23,"weekday":"Tuesday","title":"Historical volatility of Clearpoint Neuro Inc stock and its impact on investor behavior","date":"2024-01-23","url":"/posts/2024/01/23/CLPT","content":[{"section":"Definition of volatility","text":"Volatility in the stock market refers to the degree of variation in the price of a financial instrument over time. It measures the extent to which the price of a security fluctuates."},{"section":"Analysis of Clearpoint Neuro Inc stock's historical volatility","text":"Through historical analysis, it has been observed that Clearpoint Neuro Inc stock exhibits significant volatility. Fluctuations in the stock price can be attributed to various factors such as news events, financial performance, market conditions, and investor sentiment."},{"section":"Impact on investor behavior","text":"The historical volatility of Clearpoint Neuro Inc stock can impact investor behavior in several ways. High volatility may lead to increased investor caution and risk aversion. Investors may be more hesitant to buy or hold the stock due to the potential for significant price swings. Conversely, some investors may see volatility as an opportunity for profit, engaging in short-term trading strategies to take advantage of price movements."},{"section":"Risk management strategies","text":"The historical volatility of Clearpoint Neuro Inc stock necessitates the implementation of effective risk management strategies by investors. Some common risk management approaches include diversification, stop-loss orders, and setting risk tolerance levels. Diversification involves investing in a variety of assets to reduce the impact of volatility on overall portfolio performance. Stop-loss orders can help limit potential losses by automatically selling the stock if it reaches a predetermined price threshold. Setting risk tolerance levels allows investors to define an acceptable level of volatility and adjust their portfolio accordingly."},{"section":"Monitoring and adjusting investment strategies","text":"Given the historical volatility of Clearpoint Neuro Inc stock, it is imperative for investors to regularly monitor its performance and adjust their investment strategies accordingly. This may involve reviewing financial reports, news updates, and market trends to assess the potential impact on the stock's volatility. Additionally, investors should periodically evaluate their risk management practices to ensure they remain effective in mitigating the risks associated with volatility."},{"section":"Psychological impact","text":"The historical volatility of Clearpoint Neuro Inc stock can also have a psychological impact on investors. Sharp price movements and uncertain market conditions may induce fear, anxiety, or greed, which can lead to irrational investment decisions. It is important for investors to remain disciplined and rational, focusing on long-term investment goals rather than short-term price fluctuations."},{"section":"Conclusion","text":"Clearpoint Neuro Inc stock exhibits historical volatility that influences investor behavior. Understanding and managing this volatility is essential for effective risk management. By diversifying portfolios, setting risk tolerance levels, and regularly monitoring investment strategies, investors can navigate the challenges and opportunities presented by Clearpoint Neuro Inc stock's volatility."}],"tags":["CrossOver21","Long","Health Care"],"news":[{"category":"company","date":1705957500,"headline":"ClearPoint Neuro Announces First EU MDR Certification Success and Approval to Ship Product to Europe","id":125225709,"image":"https://s.yimg.com/ny/api/res/1.2/HkpHSXALmsIKohAfVQ885A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02ODY-/https://media.zenfs.com/en/globenewswire.com/926fc719bb3f33783c95d41b2e486232","symbol":"CLPT","publisher":"Yahoo","summary":"SOLANA BEACH, Calif., Jan. 22, 2024 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced receipt of European Medical Device Regulation (EU MDR) clearance for the manual SmartTwist® MR Hand Drill and SmartTip® MR Drill Kit. Additionally, the Company received updated certification from its Notified Body allowing for shipment of products manufactured at","url":"https://finance.yahoo.com/news/clearpoint-neuro-announces-first-eu-210500964.html"},{"category":"company","date":1705940160,"headline":"ClearPoint Neuro Gets EU OK For 2 Devices","id":125226683,"image":"https://mw3.wsj.net/mw5/content/logos/mw_logo_social.png","symbol":"CLPT","publisher":"MarketWatch","summary":"By Ben Glickman ClearPoint Neuro on Monday said it had received approval from European regulators for two medical devices. The Solana Beach, Calif.-based...","url":"https://www.marketwatch.com/story/clearpoint-neuro-gets-eu-ok-for-2-devices-7cd9f5ce"},{"category":"company","date":1705486347,"headline":"ClearPoint Neuro Announces FDA Clearance for SmartFrame OR Stereotactic System","id":125109946,"image":"","symbol":"CLPT","publisher":"Finnhub","summary":"SOLANA BEACH - ClearPoint Neuro, Inc. , a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced it has received 510 clearance for...","url":"https://finnhub.io/api/news?id=9aaf68aa2481f3181d62a9ac571374a332970a3f11e2f3173859bdb6cd4da7c8"},{"category":"company","date":1705410000,"headline":"ClearPoint Neuro Announces FDA Clearance for SmartFrame OR™ Stereotactic System","id":125098804,"image":"https://s.yimg.com/ny/api/res/1.2/HkpHSXALmsIKohAfVQ885A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02ODY-/https://media.zenfs.com/en/globenewswire.com/926fc719bb3f33783c95d41b2e486232","symbol":"CLPT","publisher":"Yahoo","summary":"Limited Market Release of First Purpose-Built OR Product to Begin in First Half of 2024 SmartFrame OR™ Stereotactic Systemwww.clearpointneuro.com SOLANA BEACH, Calif., Jan. 16, 2024 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced it has received 510(k) clearance for its SmartFrame OR™ Stereotactic System. The SmartFrame OR Stereotactic System is","url":"https://finance.yahoo.com/news/clearpoint-neuro-announces-fda-clearance-130000192.html"},{"category":"company","date":1705389720,"headline":"ClearPoint Neuro announces FDA clearance for SmartFrame OR system","id":125089541,"image":"","symbol":"CLPT","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3302040464"},{"category":"company","date":1705375860,"headline":"ClearPoint Neuro gets FDA clearance for SmartFrame OR","id":125111047,"image":"","symbol":"CLPT","publisher":"Seeking Alpha","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3302811848"},{"category":"company","date":1704851220,"headline":"7 Small-Cap Stocks With Huge Potential Flying Under the Radar","id":124970423,"image":"","symbol":"CLPT","publisher":"InvestorPlace","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3294455143"},{"category":"company","date":1704800760,"headline":"ClearPoint Neuro: A Strong Buy on Stellar Financials and Strategic Expansion","id":124972928,"image":"","symbol":"CLPT","publisher":"TipRanks","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3292464948"},{"category":"company","date":1704798009,"headline":"ClearPoint Neuro Shares Up 16% After Prelim. 4Q Revenue Beats Estimates","id":124945640,"image":"","symbol":"CLPT","publisher":"Finnhub","summary":"By Ben Glickman Shares of ClearPoint Neuro rose after preliminary fourth-quarter revenue topped estimates. The stock was up 16% to $7.35 in morning trading Tuesday. Shares are down 17% in...","url":"https://finnhub.io/api/news?id=62ec02cc27cb007681bdf8e57363097eee4b9a385ede9b6094e3aed24a7917ae"},{"category":"company","date":1704791040,"headline":"Cyclacel Pharmaceuticals, ClearPoint Neuro among healthcare movers","id":124970906,"image":"","symbol":"CLPT","publisher":"Seeking Alpha","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3292242263"},{"category":"company","date":1704782220,"headline":"Stifel Nicolaus Remains a Buy on ClearPoint Neuro (CLPT)","id":124972930,"image":"","symbol":"CLPT","publisher":"TipRanks","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3292065009"}]}